Anticonvulsionantes: Profilaxis de migraña
Anticonvulsants: Migraine prophylaxis
Barra lateral del artículo
PDF
FLIP
Cómo citar
Palacios, E., & Pradilla, O. (2008). Anticonvulsionantes: Profilaxis de migraña. Revista Repertorio De Medicina Y Cirugía, 17(3), 127–134. https://doi.org/10.31260/RepertMedCir.v17.n3.2008.505
Sección
Artículo de revisión
Términos de Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Contenido principal del artículo
Resumen
Múltiples medicamentos han sido utilizados en la profilaxis de la migraña y dentro de estos los anticonvulsivantes como el ácido valproico, topiramato y gabapentín han demostrado utilidad en la disminución del número y severidad de los ataques en cerca del 50%. Sus mecanismos de acción involucran interacciones con los canales de Na, K, Cl, Ca y neurotransmisores como glutamato, GABA y Ca, mediante las cuales los AC regulan la hiperexcitabilidad cortical y la disregulación neuromoduladora que constituyen las principales alteraciones fisiopatológicas en la migraña. Entre los AC el ácido valproico posee mayor acción profiláctica y similar efectividad a la lograda con propanolol. Ninguno puede considerarse de elección y la individualización del paciente es la principal guía para la selección del tipo de fármaco profiláctico. Abreviaturas: MG, migraña; AC, anticonvulsivantes; GABA, ácido gamma-aminobutírico; AMPA, ácido a-amino-3-hidroxi-5-metil-4-isoxalone propiónico; AVP, ácido valproico; TPM, topiramato; GPT, gabapentín; LTG, lamotrigina.
Palabras clave:
Descargas
Los datos de descargas todavía no están disponibles.
Detalles del artículo
Referencias
1. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001 Nov-Dec;41 Suppl 1:S3-10.
2. Post RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology. 1994 Oct;44(10 Suppl 7):S37-47.
3. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988 Oct;78(4):346-8.
4. Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007 Apr;28(4):188-95.
5. Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007 Apr;47 Suppl 1:S52-7.
6. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4):257-70.
7. Rogawski MA, Lóscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004 Jul;10(7):685-92.
8. Kelly KM. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology. 1998 Oct;38(3): 139-44.
9. Morris GL. Gabapentin. Epilepsia. 1999;40 Suppl 5:S63- 70.
10. Goadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov. 2005 Sep;4(9):741-50.
11. Magnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl 6:S66-72.
12. Glauser TA.Topiramate.Epilepsia. 1999;40 Suppl 5:S71- 80.
13. Silberstein SD. Practice parameter: evidence-based guidefines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62.
14. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001 Mar 15;21(6):1868-75.
15. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal hom through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology. 2004 Apr;46(5):743-9.
16. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache. 2004 Nov-Dec;44(10):1040-2.
17. Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci. 2005 May;26 Suppl 2:s111-20.
18. Chronicle E, Mulleners W.Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(3):CD003226.
19. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997 Apr;17(2):93-100.
20. Graff-Radford SB. Migraine Prophylaxis. Clin Fam Pract. Sep 2005;7(3):445-62.
21. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einháupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001 Sep;41(8):774-8.
22. Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004 Oct;25 Suppl 3:S161-6.
23. Taylor K, Goldstein J. High-dose versus low-dose valproic acid as a prophylactic medication. Headache. 1996 Sep;36(8):514-5.
24. Members of the task force:, Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006 Jun;13(6):560-72.
25. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994 Apr;44(4): 647-51.
26. Rothrock JF, Mendizabal JE. An analysis of the "carryover effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache. 2000 Jan;40(1):17-9.
27. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002 S ep;22(7):491-512.
28. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci. 2007 May;28 Suppl 2:S188-97.
29. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992 Apr;12(2):81-4.
30. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of to- piramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006 Apr;46(4):642-8.
31. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995 Mar;52(3):281-6.
32. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 1996 Oct;36(9):547-55.
33. Pennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol. 2002 Sep;22(3):299-308.
34. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001 Nov-Dec;41(10):968-75.
35. Silberstein SD Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci. 2004 Oct;25 Suppl 3:S244-5.
36. Silberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr;45 Suppl 1:S57-65.
37. Peres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006 Sep;7(4):185-7.
38. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007 Mar;47(3):402-12.
39. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influenceoftopiramate in the regulation of energy balance. Nutrition. 2000 Oct;16(10):961-6.
40. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41 Suppl 2:S42-52.
41. Cissoko H, Jonville-Béra AP, Autret-Leca E. [New antiepileptic drugs in pregnancy: outcome of 12 exponed pregnancies] Therapie. 2002 Jul-Aug;57(4):397-401.
42. Vila Cerén C, Demestre Guasch X, Raspall Torrent F, Elizari Saco MJ, Sala Castellví P, Martínez Nadal S. [Topiramate and pregnancy. Neonate with bone anomalies]An Pediatr (Barc). 2005 Oct;63(4):363-5.
43. Petroff 0A, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gammaaminobutyric acid in patients with epilepsy.Ann Neurol. 1996 Jan;39(1):95-9.
44. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28.
45. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000 May-Jun;151(3):145-8.
46. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 Apr;26(2):188-98.
47. Krymchantowski AV, Bigal ME, Moreira PF.New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9):611-34.
48. Silberstein SD. Preventive treatment of migraine Trends Pharmacol Sci. 2006 Aug;27(8):410-5.
2. Post RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology. 1994 Oct;44(10 Suppl 7):S37-47.
3. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988 Oct;78(4):346-8.
4. Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007 Apr;28(4):188-95.
5. Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007 Apr;47 Suppl 1:S52-7.
6. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4):257-70.
7. Rogawski MA, Lóscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004 Jul;10(7):685-92.
8. Kelly KM. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology. 1998 Oct;38(3): 139-44.
9. Morris GL. Gabapentin. Epilepsia. 1999;40 Suppl 5:S63- 70.
10. Goadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov. 2005 Sep;4(9):741-50.
11. Magnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl 6:S66-72.
12. Glauser TA.Topiramate.Epilepsia. 1999;40 Suppl 5:S71- 80.
13. Silberstein SD. Practice parameter: evidence-based guidefines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62.
14. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001 Mar 15;21(6):1868-75.
15. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal hom through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology. 2004 Apr;46(5):743-9.
16. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache. 2004 Nov-Dec;44(10):1040-2.
17. Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci. 2005 May;26 Suppl 2:s111-20.
18. Chronicle E, Mulleners W.Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(3):CD003226.
19. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997 Apr;17(2):93-100.
20. Graff-Radford SB. Migraine Prophylaxis. Clin Fam Pract. Sep 2005;7(3):445-62.
21. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einháupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001 Sep;41(8):774-8.
22. Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004 Oct;25 Suppl 3:S161-6.
23. Taylor K, Goldstein J. High-dose versus low-dose valproic acid as a prophylactic medication. Headache. 1996 Sep;36(8):514-5.
24. Members of the task force:, Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006 Jun;13(6):560-72.
25. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994 Apr;44(4): 647-51.
26. Rothrock JF, Mendizabal JE. An analysis of the "carryover effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache. 2000 Jan;40(1):17-9.
27. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002 S ep;22(7):491-512.
28. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci. 2007 May;28 Suppl 2:S188-97.
29. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992 Apr;12(2):81-4.
30. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of to- piramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006 Apr;46(4):642-8.
31. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995 Mar;52(3):281-6.
32. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 1996 Oct;36(9):547-55.
33. Pennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol. 2002 Sep;22(3):299-308.
34. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001 Nov-Dec;41(10):968-75.
35. Silberstein SD Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci. 2004 Oct;25 Suppl 3:S244-5.
36. Silberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr;45 Suppl 1:S57-65.
37. Peres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006 Sep;7(4):185-7.
38. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007 Mar;47(3):402-12.
39. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influenceoftopiramate in the regulation of energy balance. Nutrition. 2000 Oct;16(10):961-6.
40. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41 Suppl 2:S42-52.
41. Cissoko H, Jonville-Béra AP, Autret-Leca E. [New antiepileptic drugs in pregnancy: outcome of 12 exponed pregnancies] Therapie. 2002 Jul-Aug;57(4):397-401.
42. Vila Cerén C, Demestre Guasch X, Raspall Torrent F, Elizari Saco MJ, Sala Castellví P, Martínez Nadal S. [Topiramate and pregnancy. Neonate with bone anomalies]An Pediatr (Barc). 2005 Oct;63(4):363-5.
43. Petroff 0A, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gammaaminobutyric acid in patients with epilepsy.Ann Neurol. 1996 Jan;39(1):95-9.
44. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28.
45. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000 May-Jun;151(3):145-8.
46. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 Apr;26(2):188-98.
47. Krymchantowski AV, Bigal ME, Moreira PF.New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9):611-34.
48. Silberstein SD. Preventive treatment of migraine Trends Pharmacol Sci. 2006 Aug;27(8):410-5.
Citado por
